Seroepidemiology of norovirus-associated travelers' diarrhea
- PMID: 24383649
- PMCID: PMC3904865
- DOI: 10.1111/jtm.12092
Seroepidemiology of norovirus-associated travelers' diarrhea
Abstract
Background: Noroviruses (NoVs) are the most common cause of epidemic gastroenteritis, responsible for at least 50% of all gastroenteritis outbreaks worldwide and were recently identified as a leading cause of travelers' diarrhea (TD) in US and European travelers to Mexico, Guatemala, and India.
Methods: Serum and diarrheic stool samples were collected from 75 US student travelers to Cuernavaca, Mexico, who developed TD. NoV RNA was detected in acute diarrheic stool samples using reverse transcription-polymerase chain reaction (RT-PCR). Serology assays were performed using GI.1 Norwalk virus (NV) and GII.4 Houston virus (HOV) virus-like particles (VLPs) to measure serum levels of immunoglobulin A (IgA) and IgG by dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA); serum IgM was measured by capture enzyme-linked immunosorbent assay (ELISA), and the 50% antibody-blocking titer (BT50 ) was determined by a carbohydrate-blocking assay.
Results: NoV infection was identified in 12 (16%; 9 GI-NoV and 3 GII-NoV) of 75 travelers by either RT-PCR or fourfold or more rise in antibody titer. Significantly more individuals had detectable preexisting IgA antibodies against HOV (62/75, 83%) than against NV (49/75, 65%) (p = 0.025) VLPs. A significant difference was observed between NV- and HOV-specific preexisting IgA antibody levels (p = 0.0037), IgG (p = 0.003), and BT50 (p = <0.0001). None of the NoV-infected TD travelers had BT50 > 200, a level that has been described previously as a possible correlate of protection.
Conclusions: We found that GI-NoVs are commonly associated with TD cases identified in US adults traveling to Mexico, and seroprevalence rates and geometric mean antibody levels to a GI-NoV were lower than to a GII-NoV strain.
© 2014 International Society of Travel Medicine.
Conflict of interest statement
R.L.A. has received research support from Takeda Vaccines (Montana), Inc. M.K.E. received support from NIH7NIAID to conduct the study. She is an inventor on patents related to cloning of the Norwark virus genome and is a consultant to Takeda Vaccines (Montana), Inc.
The other authors state they have no conflicts of interest to declare.
Figures
Comment in
-
Norovirus diagnostics and serology in travelers' diarrhea-where do we go from here?J Travel Med. 2014 Jan-Feb;21(1):1-3. doi: 10.1111/jtm.12091. J Travel Med. 2014. PMID: 24383647 No abstract available.
References
-
- NCfI Division of Viral Diseases, CfDC Respiratory Diseases, Prevention. Updated norovirus outbreak management and disease prevention guidelines. MMWR Recomm Rep. 2011;60(RR-3):1–18. - PubMed
-
- Zheng DP, Ando T, Fankhauser RL, et al. Norovirus classification and proposed strain nomenclature. Virology. 2006;346(2):312–23. - PubMed
-
- Wikswo ME, Hall AJ. Outbreaks of acute gastroenteritis transmitted by person-to-person contact - united states, 2009–2010. MMWR Surveill Summ. 2012;61(9):1–12. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
